Ask AI
ProCE Banner Activity

2025 San Antonio Breast Cancer Symposium Conference Coverage: Highlights Podcast

Conference Coverage
Podcast Episodes

Listen to breast cancer experts discussing clinical highlights from a recent webinar on new data and clinical updates presented at the 2025 San Antonio Breast Cancer Symposium, including answers to outstanding questions in the field of breast cancer care.

Released: March 09, 2026

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

Gilead Sciences, Inc.

Lilly

Novartis Pharmaceuticals Corporation

Stemline Therapeutics, Inc.

Target Audience

The goal of this activity is to improve learners’ understanding of how to optimally apply recent practice-changing findings in treating patients with breast cancer. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify subpopulations of patients with breast cancer most likely to benefit from a specific treatment plan based on predictive biomarkers

  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with breast cancer
  • Evaluate new data on novel agents and therapeutic approaches for patients with breast cancer

Faculty Disclosure

Primary Author

Virginia Kaklamani, MD, DSc: consultant/advisor/speaker: AstraZeneca, Genentech, Gilead, Lilly, Menarini.

Sara M. Tolaney, MD, MPH: consultant/advisor: Aadi Bio, Artios Pharma, Arvinas, AstraZeneca, Atkis Oncology, Avenzo, Bayer, BeOne, Blueprint Medicines, Bicycle Therapeutics, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb/Systimmune, Celcuity, Circle Pharma, Cullinan Oncology, Daiichi Sankyo, eFFECTOR, Eisai, Genentech/Roche, Gilead, Hengrui USA, Jazz, Johnson & Johnson/Ambrx, Launch Therapeutics, Lilly, Menarini/Stemline, Merck, Mersana, Natera, Novartis, Olema, Pfizer/SeaGen, Reveal Genomics, Samsung Bioepis, Summit, Sumitovant, Tango, Tempus, Zuellig; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Exelixis, Genentech/Roche, Gilead, Jazz, Lilly, Menarini/Stemline, Merck, NanoString, Novartis, OncoPep, Pfizer/SeaGen; other financial or material support: Arvians, AstraZeneca, Gilead, Jazz, Lilly, Pfizer, Roche.